Alacris Theranostics GmbH / Alacris Theranostics GmbH Announces Illumina CSPro Certification for Next Generation Sequencing . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement.
Berlin, Germany, June 11, 2013 - Alacris Theranostics GmbH announced today that it has successfully completed Illumina CSPro(TM) certification for next generation sequencing (NGS); gaining entry to an elite global group of Illumina genomics service providers. Illumina Inc., a San Diego-based company, provides leading-edge genetic analysis tools to genomics centers worldwide.
Illumina CSPro is the collaborative service provider partnership dedicated to ensuring the delivery of the highest-quality data available for genetic analysis applications. Illumina CSPro participants undergo a rigorous two-phase certification process that includes minimum data generation, data certification, and an on-site audit of the facility and processes.
"Alacris Theranostics is advancing the field of personalised medicine by developing new approaches for the prediction of drug treatments. To this end the company is applying its proprietary systems biology model, ModCell(TM) for use in drug development projects for Pharma and patient stratification in clinical research projects. For the development of ModCell(TM) high quality NGS data provided for example through the Illumina technology is the basis for precise modelling predictions. Alacris also provides expertise in sequencing, analysis and mathematical modelling within global personalised medicine-oriented projects (for example OncoTrack (www.oncotrack.eu (http://www.oncotrack.eu/))). Becoming an Illumina CSPro for NGS is valuable confirmation of Alacris Theranostics' excellent management, laboratory and analysis standards, important for both the company and its clients."
"Illumina CSPro recognizes organizations that provide customers with industry-leading data quality and service in genetic analysis," said Karen Possemato, Illumina's Sr. Director of Corporate Marketing. Now that Alacris Theranostics is a global CSPro partner, we are excited to work with them to make it easier for researchers in Germany to access the power of Illumina's genetic analysis technologies."
About Alacris Theranostics
Alacris Theranostics GmbH is a Berlin-based company specialising in the development of new personalised medicine approaches for cancer patient diagnosis, treatment and drug stratification. Using its proprietary virtual patient model ModCell(TM) Alacris can perform personalised prediction of drug treatments, supporting its clients for drug development and in clinical trials by matching patients to therapies and therapies to patients. The Alacris Theranostics team has a strong background in academic cancer research and collaborates closely with oncologists and pharmaceutical companies worldwide. It also possesses extensive expertise in all aspects of NGS, from initial experimental design through to the comprehensive analysis of sequence data, offering this service also for a wide range of applications, including whole genome and targeted sequencing, ChIP-Seq, RNA-Seq and microRNA/small RNA analysis of (clinical) tumor and normal tissue samples.
Contact:
Alacris Theranostics GmbH
Dr. B. Lange
Fabeckstrasse 60-62
D-14195 Berlin
Phone: +49 30 8413-1471
Fax: +49 30 8413-1465
Email: info@alacris.de (mailto:info@alacris.de)
Web: www.alacris.de (http://www.alacris.de)
MC Services AG
Anne Hennecke, Managing Partner
Phone: +49 89 210 228 18
Email: anne.hennecke@mc-services.eu (mailto:anne.hennecke@mc-services.eu)
The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.
Source: Alacris Theranostics GmbH via Thomson Reuters ONE
--- End of Message ---
Alacris Theranostics GmbH
Fabeckstrasse 60-62 Berlin Germany
